山东大学耳鼻喉眼学报 ›› 2019, Vol. 33 ›› Issue (2): 136-138.doi: 10.6040/j.issn.1673-3770.0.2018.317

• 综述 • 上一篇    

缺氧诱导因子-1α在甲状腺癌中的调节机制

宋晓宇1,2,宋西成1,2   

  1. 1.滨州医学院, 山东 烟台 264003;
    2.青岛大学附属烟台毓璜顶医院耳鼻咽喉头颈外科, 山东 烟台 264000
  • 发布日期:2019-03-28
  • 作者简介:宋晓宇. E-mail:18254577511@163.com
  • 基金资助:
    山东省重点研发计划项目(2015GSF118090);山东省2013年度留学人员科研活动择优资助项目(鲁人社字[2013]528号)

Research progress on the regulation of HIF-1α expression in thyroid carcinoma

SONG Xiaoyu1,2, SONG Xicheng1,2   

  1. Department of Otorhinolaryngology Head and Neck Surgery, Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, Shandong, China
  • Published:2019-03-28

摘要: 肿瘤组织内局部缺氧是导致肿瘤预后差的重要因素,缺氧诱导因子-1α(Hypoxia-inducible factor -1a, HIF-1α)是低氧环境下促进肿瘤侵袭、转移的主要调节因子,其在肿瘤细胞内的表达作用与多种因素有关。HIF-1α在甲状腺癌中的调节机制可能与BRAFV600E调控、HIF-1α、CXCR4和VEGF表达调节、PTEN表达调节、CD44V6表达调节有关。

关键词: 甲状腺肿瘤, 肿瘤内缺氧, 缺氧诱导因子-1α

Abstract: Intratumoral hypoxia is an important factor leading to poor tumor prognosis. Hypoxia inducible factor-1α(HIF-1α)is the major regulatory factor promoting tumor invasion and metastasis, and its expression in tumor cells is related to several factors. The regulatory mechanism of HIF-1α in thyroid carcinoma may be related to BRAFV600E regulation and regulation of CXCR4, VEGF, PTEN, and CD44V6 expression.

Key words: Thyroid neoplasms, Tumor hypoxia microenvironment, Hypoxia inducible factor-1α

中图分类号: 

  • R736.1
[1] 王旎, 董超然, 唐萃, 等. HIF-1α、HIF-2α和MT在人甲状腺乳头状癌中的表达及其意义[J]. 中国免疫学杂志, 2014, 30(5): 662-665,676. doi: 10.3969/j.issn.1000-484X.2014.05.020. WANG Ni, DONG Chaoran, TANG Cui, et al. Expression and significance of HIF-1α, HIF-2αand MT in human papillary thy-roid carcinoma[J]. Chinese Journal of Immunology, 2014, 30(5): 662-665,676. doi: 10.3969/j.issn.1000-484X.2014.05.020.
[2] 李莹莹, 宋西成. DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 102-105,108. LI Yingying, SONG Xicheng. Advances on genetic polymorphism of DNA double-strand break repair genes and thyroid carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2016, 30(2): 102-105,108.
[3] Marin-Hernandez A, Gallardo-Perez J, Ralph S, et al. HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms[J]. Mini-Rev Med Chem, 2009, 9(9): 1084-1101. doi: 10.2174/138955709788922610.
[4] Mahkamova K, Latar N, Aspinall S, et al. Hypoxia increases thyroid cancer stem cell-enriched side population[J]. World J Surg, 2018, 42(2): 350-357. doi: 10.1007/s00268-017-4331-x.
[5] Liu YM, Ying SP, Huang YR, et al. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma[J]. World J Surg Onc, 2015, 14: 30. doi:10.1186/s12957-016-0785-9.
[6] Klaus A, Fathi O, Tatjana TW, et al. Expression of hypoxia-associated protein HIF-1α in follicular thyroid cancer is associated with distant metastasis[J]. Pathol Oncol Res, 2018, 24(2): 289-296. doi: 10.1007/s12253-017-0232-4.
[7] Jó?wiak P, Ciesielski P, Zaczek A, et al. Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions[J]. J Biomed Sci, 2017, 24: 83. doi:10.1186/s12929-017-0388-y.
[8] Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression[J]. Trends Cancer, 2016, 2(12): 758-770. doi:10.1016/j.trecan.2016.10.016.
[9] 李大伟, 董频. 缺氧诱导因子-1α在头颈肿瘤中的研究进展[J]. 现代肿瘤医学, 2010, 18(8): 1650-1652. doi: 10.3969/j.issn.1672-4992.2010.08.74.
[10] 魏晓萍, 惠起源, 王圣巍. 缺氧诱导因子1α与胃癌治疗研究的新进展[J]. 天津医药, 2011, 39(3): 283-285. doi: 10.3969/j.issn.0253-9896.2011.03.038.
[11] Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1[J]. Mol Pharmacol, 2006, 69(2): 411-418. doi: 10.1124/mol.105.015743.
[12] Tan C, Zhang L, Cheng X, et al. Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells[J]. Exp Biol Med(Maywood), 2015, 240(7): 925-935. doi:10.1177/1535370214555665.
[13] Burrows N, Resch J, Cowen RL, et al. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas[J]. Endocr Relat Cancer, 2010, 17(1): 61-72. doi: 10.1677/ERC-08-0251.
[14] Shi CL, Guo Y, Lv Y, et al. Clinicopathological features and prognosis of papillary thyroid microcarcinoma for surgery and relationships with the BRAFV600E mutational status and expression of angiogenic factors[J]. PLoS One, 2016, 11(12): e0167414. doi:10.1371/journal.pone.0167414.
[15] Zerilli M, Zito G, Martorana A, et al. BRAF(V600E)mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer[J]. Mod Pathol, 2010, 23(8): 1052-1060. doi: 10.1038/modpathol.2010.86.
[16] Zhou DH, Li Z, Bai XF. BRAFV600E and RET/PTC promote proliferation and migration of papillary thyroid carcinoma cells in vitro by regulating nuclear factor-κb[J]. Med Sci Monit, 2017, 23: 5321-5329.
[17] 李金国, 宋西成. 甲状腺癌相关信号传导通路的研究进展[J]. 肿瘤学杂志, 2018, 24(4): 293-296. doi: 10.11735/j.issn.1671-170X.2018.04.B001. LI Jinguo, SONG Xicheng, LI Jinguo, et al. Research progress of thyroid cancer related signaling pathways[J]. Journal of Chinese Oncology, 2018, 24(4): 293-296. doi: 10.11735/j.issn.1671-170X.2018.04.B001.
[18] Lim JH, Lee ES, You HJ, et al. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion[J]. Oncogene, 2004, 23(58): 9427-9431. doi: 10.1038/sj.onc.1208003.
[19] Chen HW, Feng JN, Zhang YC, et al. Pien tze Huang inhibits hypoxia-induced angiogenesis via HIF-1 α /VEGF-a pathway in colorectal cancer[J]. Evid Based Complement Alternat Med, 2015, 2015: 454279. doi:10.1155/2015/454279.
[20] 李延辉, 吴伟群, 何小杰, 等. HIF-1α、VEGF在甲状腺肿瘤中的表达及其与肿瘤血管生成的关系[J]. 中国现代医生, 2013, 51(20): 73-75. LI Yanhui, WU Weiqun, HE Xiaojie, et al. Expression of HIF-1α, VEGF and correlation with tumor angiogenesis in thyroid tumors[J]. China Modern Doctor, 2013, 51(20): 73-75.
[21] Shin DY, Kim KJ, Ku CR, et al. Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma[J]. Endocr Pathol, 2013, 24(4): 169-176. doi: 10.1007/s12022-013-9259-6.
[22] 冉程, 高永平, 张建阳, 等. 缺氧诱导因子1α、血管内皮生长因子及CXCR4受体在甲状腺乳头状癌中的表达及与肿瘤转移的关系[J]. 中国耳鼻咽喉头颈外科, 2017, 24(5): 262-264. doi: 10.16066/j.1672-7002.2017.05.009.
[23] 蔡兆根, 陆国玉, 承泽农, 等. HIF-1a、VEGF和CXCR4在甲状腺乳头状癌中的表达及意义[J]. 中国组织化学与细胞化学杂志, 2015, 24(1): 50-55. doi: 10.3870/zgzzhx.2015.01.009. CAI Zhaogen, LU Guoyu, CHENG Zenong, et al. Expression of HIF-1a, CXCR4 and VEGF in papillary thyroid carcinoma and Its significance[J]. Chinese Journal of Histochemistry and Cytochemistry, 2015, 24(1): 50-55. doi: 10.3870/zgzzhx.2015.01.009.
[24] Zhang P, Dong L, Yan K, et al. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF[J]. Oncol Rep, 2013, 30(4): 1753-1761. doi: 10.3892/or.2013.2619.
[25] Yugang Wu, Min Jin, Huanbai Xu, Zhang Shimin, Songbing He. Clinicopathologic Significance of HIF-1α, CXCR4, and VEGF Expression in Colon Cancer[J]. Clinical & Developmental Immunology, 2010(2010): 1-10. pii: 537531
[26] 赵红霞. PTEN与肿瘤的相关性研究进展[J]. 武汉大学学报(医学版), 2014, 35(1): 155-159. ZHAO Hongxia. Research progress in PTEN and tumor development[J]. Medical Journal of Wuhan University, 2014, 35(1): 155-159.
[27] 董斌. 甲状腺乳头状癌组织中HIF-1α和PTEN的表达及诊断价值[J]. 肿瘤基础与临床, 2017, 30(2): 159-160. doi:10.3969/j.issn.1673-5412.2017.02.024.
[28] Gu J, Daa T, Kashima K, et al. Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells[J]. Pathol Int, 1998, 48(3): 184-190.
[29] 曲明辉, 张洪旺, 王丹, 等. 缺氧诱导因子-1α和CD44 v6在甲状腺乳头状癌中的表达及意义[J]. 潍坊医学院学报, 2014, 36(3): 192-194. doi: 10.3969/j.issn.1004-3101.2014.03.010. QU Minghui, ZHANG Hongwang, WANG Dan, et al. Expression and significance of hypoxia-inducible factor-1αand CD44v6 in papillary thyroid carcinoma[J]. Acta Academiae Medicinae Weifang, 2014, 36(3): 192-194. doi:10.3969/j.issn.1004-3101.2014.03.010.
[30] Figge J, del Rosario AD, Gerasimov G, et al. Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma[J]. Exp Mol Pathol, 1994, 61(3): 203-211.
[1] 李浩,李延忠,王岩. HIF-1α、VEGF在阻塞性睡眠呼吸暂停低通气综合征患者[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 43-47.
[2] 陈晓红. 遗传型甲状腺髓样癌的精准化治疗[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 23-27.
[3] 王宇,马奔. 超声引导下热消融技术尚不适用于甲状腺癌及甲状腺滤泡性肿瘤治疗[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 20-22.
[4] 房居高. 强化手术技能和规范诊疗是提高甲状腺癌疗效的根本[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 1-4.
[5] 龚单春,张海东,张庆翔,何双八,于振坤. 精细化甲状腺腺叶切除操作技术[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 5-9.
[6] 徐增瑞, 张建新, 石继红, 蔡晓岚. 异种脱细胞真皮基质修复膜修复甲状腺癌切除术后气管缺损13例[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 52-54.
[7] 庄大勇,贺青卿,范子义,郑鲁明,朱见,周鹏,段松建,岳涛,董学峰. 术中神经监测技术在分化型甲状腺癌再次手术中的应用[J]. 山东大学耳鼻喉眼学报, 2013, 27(6): 5-8.
[8] 刘新义,刘 艳,李颂军,李大建,薛令军 . 甲状腺微小癌的临床特征及早期诊断[J]. 山东大学耳鼻喉眼学报, 2008, 22(1): 29-31 .
[9] 赵雪柠,叶 萍 综述, 潘新良,雷大鹏 审校 . 晚期甲状腺癌累及喉、气管和食管的外科治疗[J]. 山东大学耳鼻喉眼学报, 2007, 21(3): 260-262 .
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!